29.05.2024 - WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B ...